Sign In
Buy CHSCL
$25.35
-0.150 (-0.588%)
At Close: Jun 22, 2026
Calgary, Alberta--(Newsfile Corp. - May 22, 2026) - Comprehensive Healthcare Systems Inc. (TSXV: CHS) (OTCQB: CMHSF) (the "Company" or "CHS"), a provider of healthcare benefits administration software
CORRECTING and REPLACING CHS Reports Second Quarter Fiscal Year 2026 Earnings
01:05pm, Wednesday, 08'th Apr 2026
ST. PAUL, Minn.--(BUSINESS WIRE)--Second sentence of the paragraph under the "Energy" subtitle should read: "Energy reported a pretax loss of $133.6 million for the second quarter of fiscal year 2026,
CHS Reports Second Quarter Fiscal Year 2026 Earnings
11:22am, Wednesday, 08'th Apr 2026
ST. PAUL, Minn.--(BUSINESS WIRE)--CHS Inc. today released results for its second quarter of fiscal year 2026.
Join Comprehensive Healthcare Systems' Exclusive Live Investor Webinar and Q&A Session on February 25
06:30am, Friday, 20'th Feb 2026
Calgary, Alberta--(Newsfile Corp. - February 20, 2026) - Comprehensive Healthcare Systems Inc. (TSXV: CHS) (OTCQB: CMHSF) (the "Company" or "CHS"), an industry leader in healthcare benefits administra
Comprehensive Healthcare Systems Inc. Engages RedChip Companies to Lead Investor Relations Efforts
06:30am, Tuesday, 13'th Jan 2026
Calgary, Alberta--(Newsfile Corp. - January 13, 2026) - Comprehensive Healthcare Systems Inc. (TSXV: CHS) (OTCQB: CMHSF) (the "Company" or "CHS"), an industry leader in healthcare benefits administrat
CHS Reports First Quarter Fiscal 2026 Earnings
11:19am, Wednesday, 07'th Jan 2026
ST. PAUL, Minn.--(BUSINESS WIRE)--CHS today reports first quarter fiscal 2026 earnings. Net income of $260.5 million reflects strong energy results.
-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical
Coherus Oncology: Five Readouts Or More Possible In 2026
10:43am, Wednesday, 01'st Oct 2025
Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. The company could report readouts from its drugs in three indications in H1 2026: casdozokitug in hepatoce
Comprehensive Healthcare Systems Inc. Begins Trading on the OTCQB Markets Under the Symbol CMHSF
07:01am, Monday, 21'st Jul 2025
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2025) - Comprehensive Healthcare Systems Inc. (TSXV: CHS) (OTCQB: CMHSF) ("CHS" or the "Company"), a leading Software-as-a-Service (SaaS) provid
Comprehensive Healthcare Systems Q2 Update: Leading Healthcare Innovation with Robust Growth and Strategic Vision
07:01am, Wednesday, 16'th Jul 2025
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2025) - Comprehensive Healthcare Systems Inc. (TSXV: CHS) ("CHS" or the "Company"), a leading Software-as-a-Service (SaaS) provider revolutioniz
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
04:15pm, Monday, 12'th May 2025
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presente
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports exp
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract high
FRANKLIN, Tenn. & AUSTIN, Texas--(BUSINESS WIRE)--Community Health Systems, Inc. (NYSE: CYH) (“CHS”) and Denim Health have announced a development partnership that is aimed at revolutionizing the
